GlassScriptPhysician profile
Kenneth W Myers
NPI 1538159777
$12,399.35
in general payments reported to CMS, 2019-2025
39 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,852 · 2020: $1,174 · 2021: $1,819 · 2022: $1,766 · 2023: $1,894 · 2024: $1,916 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,753 · Education: $34.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,753.35 |
| Education | $34.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,847.30 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Csl Behring | $1,626.51 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,361.09 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,264.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,079.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $826.22 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Teva Pharmaceuticals USA, INC. | $551.43 | 2020-2023 | Airduo Digihaler |
| Biocryst US Sales Co., LLC | $468.93 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $453.56 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Genentech USA, INC. | $393.30 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $360.37 | 2019-2025 | |
| Amgen INC. | $312.68 | 2021-2025 | Tezspire |
| Kaleo, INC. | $258.34 | 2019-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $204.67 | 2019-2025 | Ruconest |
| Optinose US, INC. | $184.45 | 2019-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.